This issue really stinks. The cost of this issue is high. 1)...

This issue really stinks. The cost of this issue is high. 1) discount to prevailing price 2) 6% in fees and a further 2.8% of shares as options. All at the expense of existing shareholders ( except management who also have their snout in the trough).

If this company becomes valuable, the options could be worth a lot of money - all at the expense of existing shareholders who miss out. Management probably threw these in as they probably thought "it costs nothing". Yea. it only costs nothing if this company is a dud - and we surely hope that is not the case. If the company goes to say a dollar a share for example, this becomes a very expensive capital raise. And all retail shareholders miss out.

I also bet Canacord and other institutions will also want to sell out at a quick profit and further depress the share price.

Oh the joys of being a retail investor when the decks are tilted against you.